Paul Stuart Meltzer

US Patent:

6562589, May 13, 2003

Filed:

Aug 21, 1998

Appl. No.:

09/125635

Inventors:

Paul Meltzer - Rockville MD
Jeffrey Trent - Paradise Valley AZ

Assignee:

The United States of America as represented by the Department of Health and Human Services - Washington DC

International Classification:

C07H 2104

US Classification:

435 691, 6 71, 61723, 6235, 63201, 6325, 62523, 536 235, 536 243, 536 231, 536 234, 530300, 530350

Abstract:

The invention features a substantially pure DNA which includes a sequence encoding a novel steroid receptor co-activator which is overexpressed in breast cancer cells, diagnostic assays for steroid hormone-responsive cancers, and screening assays to identify compounds which inhibit an interaction of the co-activator with the steroid hormone.

US Patent:

7232890, Jun 19, 2007

Filed:

Mar 4, 2003

Appl. No.:

10/379616

Inventors:

Paul Meltzer - Rockville MD, US
Jeffrey M. Trent - Paradise Valley AZ, US

Assignee:

The United States of America as represented by the Department of Health and Human Services - Washington DC

International Classification:

C07K 16/00

US Classification:

5303879, 5303881, 5303871, 5303891, 530350

Abstract:

The invention features a substantially pure DNA which includes a sequence encoding a novel steroid receptor co-activator which is overexpressed in breast cancer cells, diagnostic assays for steroid hormone-responsive cancers, and screening assays to identify compounds which inhibit an interaction of the co-activator with the steroid hormone.

US Patent:

7247426, Jul 24, 2007

Filed:

Aug 2, 2001

Appl. No.:

09/921406

Inventors:

Zohar Yakhini - Yaacov, IL
Michael Bittner - Rockville MD, US
Jeff Trent - Rockville MD, US
Amir Ben-Dor - Bellevue WA, US
Paul Meltzer - Rockville MD, US
Yidong Chen - Rockville MD, US
Ashani Weeraratna - Owings Mil MD, US
Yuan Jiang - Gaithersburg MD, US
Nick Sampas - San Jose CA, US
Edward Dougherty - College Station TX, US

Assignee:

Agilent Technologies, Inc. - Santa Clara CA

International Classification:

C12Q 1/68

US Classification:

435 6, 436 64, 436501, 436518

Abstract:

The overexpression of certain marker genes including Wnt5a has been found useful in the identification of more aggressive forms of malignant melanoma. Therefore, the overexpression of these genes in tumor samples of malignant melanoma may be useful in the diagnosis, profiling, and treatment of patients suffering from this disease. Inhibitors of Wnt5a activity may be useful in the treatment of aggressive forms of malignant melanoma. Inhibition of Wnt5a activity may be effected by any method including anti-sense therapy, gene therapy, and pharmaceutical intervention.

US Patent:

7655397, Feb 2, 2010

Filed:

May 31, 2002

Appl. No.:

10/159563

Inventors:

Javed Khan - Derwood MD, US
Markus Ringnér - Lund, SE
Carsten Peterson - Lund, SE
Paul Meltzer - Rockville MD, US

Assignee:

The United States of America as represented by the Department of Health and Human Services - Washington DC

International Classification:

C12Q 1/68
C12P 19/34
C07H 21/02
C07H 21/04

US Classification:

435 6, 435 911, 435 912, 435 9121, 435 915, 435 9151, 536 235

Abstract:

A method of diagnosing a disease that includes obtaining experimental data on gene selections. The gene selection functions to characterize a cancer when the expression of that gene selection is compared to the identical selection from a noncancerous cell or a different type of cancer cell. The invention also includes a method of targeting at least one product of a gene that includes administration of a therapeutic agent. The invention also includes the use of a gene selection for diagnosing a cancer.

US Patent:

7774143, Aug 10, 2010

Filed:

Apr 25, 2002

Appl. No.:

10/133937

Inventors:

Javed Khan - Derwood MD, US
Markus Ringnér - Lund, SE
Carsten Peterson - Lund, SE
Paul Meltzer - Rockville MD, US

Assignee:

The United States of America as represented by the Secretary, Department of Health and Human Services - Washington DC

International Classification:

G06F 19/00
G06F 17/10
G06N 3/00
G06G 7/00
G06G 7/58

US Classification:

702 19, 706 13, 706 15, 703 2, 703 11

Abstract:

A method of diagnosing, predicting, or prognosticating about a disease that includes obtaining experimental data, wherein the experimental data is high dimensional data, filtering the data, reducing the dimensionality of the data through use of one or more methods, training a supervised pattern recognition method, ranking individual data points from the data, wherein the ranking is dependent on the outcome of the supervised pattern recognition method, choosing multiple data points from the data, wherein the choice is based on the relative ranking of the individual data points, and using the multiple data points to determine if an unknown set of experimental data indicates a diseased condition, a predilection for a diseased condition, or a prognosis about a diseased condition.

US Patent:

7783431, Aug 24, 2010

Filed:

Oct 30, 2007

Appl. No.:

11/928901

Inventors:

Javed Khan - Derwood MD, US
Markus Ringner - Lund, SE
Carsten Peterson - Lund, SE
Paul Meltzer - Rockville MD, US

Assignee:

The United States of America as represented by the Department of Health and Human Services - Washington DC

International Classification:

G06F 19/00
G06F 17/10
G06N 3/00
G06G 7/00
G06G 7/58

US Classification:

702 19, 702 13, 702 15, 703 2, 703 11

Abstract:

A method of diagnosing, predicting, or prognosticating about a disease that includes obtaining experimental data, wherein the experimental data is high dimensional data, filtering the data, reducing the dimensionality of the data through use of one or more methods, training a supervised pattern recognition method, ranking individual data points from the data, wherein the ranking is dependent on the outcome of the supervised pattern recognition method, choosing multiple data points from the data, wherein the choice is based on the relative ranking of the individual data points, and using the multiple data points to determine if an unknown set of experimental data indicates a diseased condition, a predilection for a diseased condition, or a prognosis about a diseased condition.

US Patent:

8065092, Nov 22, 2011

Filed:

Aug 18, 2010

Appl. No.:

12/858674

Inventors:

Javed Khan - Derwood MD, US
Markus Ringnér - Lund, SE
Carsten Peterson - Lund, SE
Paul Meltzer - Rockville MD, US

Assignee:

The United States of America as represented by the Department of Health and Human Services - Washington DC

International Classification:

G06F 19/00
G06F 17/10
G06N 3/00
G06G 7/00
G06G 7/58

US Classification:

702 19, 702 13, 702 15, 703 2, 703 11

Abstract:

A method of diagnosing, predicting, or prognosticating about a disease that includes obtaining experimental data, wherein the experimental data is high dimensional data, filtering the data, reducing the dimensionality of the data through use of one or more methods, training a supervised pattern recognition method, ranking individual data points from the data, wherein the ranking is dependent on the outcome of the supervised pattern recognition method, choosing multiple data points from the data, wherein the choice is based on the relative ranking of the individual data points, and using the multiple data points to determine if an unknown set of experimental data indicates a diseased condition, a predilection for a diseased condition, or a prognosis about a diseased condition.

US Patent:

8263759, Sep 11, 2012

Filed:

Oct 30, 2007

Appl. No.:

11/981502

Inventors:

Javed Khan - Derwood MD, US
Markus Ringner - Lund, SE
Carsten Peterson - Lund, SE
Paul Meltzer - Rockville MD, US

Assignee:

The United States of America, as Represented by the Secretary, Department of Health and Human Services - Washington DC

International Classification:

C07H 21/02
C07H 21/04
C12Q 1/68

US Classification:

536 2431, 536 235, 536 2433, 435 61, 435 611, 435 614, 4352872

Abstract:

A method of diagnosing a disease that includes obtaining experimental data on gene selections. The gene selection functions to characterize a cancer when the expression of that gene selection is compared to the identical selection from a noncancerous cell or a different type of cancer cell. The invention also includes a method of targeting at least one product of a gene that includes administration of a therapeutic agent. The invention also includes the use of a gene selection for diagnosing a cancer.